DelveInsight’s, “Bile Duct Cancer Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Bile Duct Cancer pipeline landscape. It covers the Bile Duct Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bile Duct Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight’s comprehensive Bile Duct Cancer Pipeline Drugs Report @ Bile Duct Cancer Pipeline Outlook Report
Key Takeaways from the Bile Duct Cancer Pipeline Report
- On March 05, 2026- Endeavor Biomedicines Inc. conducted a phase 2 study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.
- On March 04, 2026- AstraZeneca announced a Phase III, randomized, double-blind, placebo-controlled, multicenter, global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1(tegafur/ gimeracil/ oteracil) or gemcitabine/cisplatin) as adjuvant treatment in participants with BTC after resection with curative intent. This study will be conducted in patients with BTC who are at risk of recurrence after resection with curative intent.
- On March 02, 2026- Eisai Co. Ltd initiated a phase 2 study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable cholangiocarcinoma with FGFR2 gene fusion who failed gemcitabine-based combination chemotherapy.
- DelveInsight’s Bile Duct Cancer pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Bile Duct Cancer treatment.
- The leading Bile Duct Cancer Companies such as Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
- Promising Bile Duct Cancer Therapies such as GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.
Access DelveInsight’s in-depth Bile Duct Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Bile Duct Cancer Clinical Trials and Studies
Bile Duct Cancer Overview
Cholangiocarcinoma is an aggressive malignancy that originates from the biliary epithelium, both inside and outside the liver. Certain preexisting conditions and diseases can increase the risk of developing cholangiocarcinoma. This neoplasm is difficult to diagnose because obtaining a tissue sample for confirmation is not always possible. Unfortunately, cholangiocarcinoma is often locally invasive or metastatic by the time it is detected. While surgery is the only cure, radiation, chemotherapy, and targeted therapy can also be used in conjunction with surgery. It is classified by anatomical origin as intrahepatic cholangiocarcinoma (iCCA) or extrahepatic cholangiocarcinoma (eCCA); eCCA is subdivided into perihilar cholangiocarcinoma (pCCA) and distal cholangiocarcinoma (dCCA). More than 95% of cholangiocarcinomas are adenocarcinomas.
Bile Duct Cancer Emerging Drugs Profile
- TT-00420: TransThera Biosciences
TT-00420 is an innovative, global phase III stage spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Ongoing clinical trials in the US and China have revealed the potential of TT-00420 to be efficacious in various solid tumors. It was granted the Orphan-Drug Designation and Fast Track Designation by the FDA for the treatment of CCA. In July 2023, TT-00420 was granted the Breakthrough Therapy Designation (BTD) by NMPA in China.
- VG161: Virogin Biotech
VG161, Virogin’s pioneering oncolytic virus built on the company’s proprietary SynerlyticTM Platform, is an attenuated herpes simplex virus type 1 (HSV-1) armed with multiple payloads of IL12 & IL15/IL15Ra and a unique PD-L1 blocking peptide. The neurovirulence of wild-type HSV-1 is mitigated by the deletion of ICP 34.5 gene. These payloads can synergistically stimulate both innate and adaptive anti-tumor immunity in the tumor microenvironment. VG161 has been confirmed to be safe and effective in many tumor xenograft mouse models and in GLP toxicity studies preclinically. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cholangiocarcinoma.
- NXP800: Nuvectis Pharma
NXP800 is an oral, small molecule, potentially first-in-class GCN2 kinase activator. NXP800 is also being evaluated in an investigator-initiated study conducted in collaboration with the Mayo Clinic for the treatment of cholangiocarcinoma, an indication for which the FDA granted NXP800 Orphan Drug Designation. The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted Fast Track Designation by the FDA. NXP800 completed a Phase 1a dose-escalation study in the first half of 2023. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Cholangiocarcinoma.
The Bile Duct Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Bile Duct Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bile Duct Cancer Treatment.
- Bile Duct Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Bile Duct Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bile Duct Cancer market.
Get a detailed analysis of the latest innovations in the Bile Duct Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Bile Duct Cancer Unmet Needs
Bile Duct Cancer Companies
Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
Bile Duct Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Bile Duct Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download DelveInsight’s latest report to gain strategic insights into upcoming Bile Duct Cancer Therapies and Developments @ Bile Duct Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Bile Duct Cancer Pipeline Report
- Coverage- Global
- Bile Duct Cancer Companies- Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
- Bile Duct Cancer Therapies- GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.
- Bile Duct Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Bile Duct Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find out in DelveInsight’s exclusive Bile Duct Cancer Pipeline Report—access it now! @ Bile Duct Cancer Emerging Drugs and Major Companies
Table of Content
- Introduction
- Executive Summary
- Bile Duct Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Bile Duct Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- TT-00420: TransThera Biosciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- VG161: Virogin Biotech
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- NXP800: Nuvectis Pharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Bile Duct Cancer Key Companies
- Bile Duct Cancer Key Products
- Bile Duct Cancer- Unmet Needs
- Bile Duct Cancer- Market Drivers and Barriers
- Bile Duct Cancer- Future Perspectives and Conclusion
- Bile Duct Cancer Analyst Views
- Bile Duct Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/bile-duct-cancer-cholangiocarcinoma-pipeline-insight
